keyword
MENU ▼
Read by QxMD icon Read
search

"immune checkpoint inhibitor"

keyword
https://www.readbyqxmd.com/read/29241377/current-and-future-immunotherapies-for-thyroid-cancer
#1
Alessandro Antonelli, Silvia Martina Ferrari, Poupak Fallahi
Cancer immunotherapies were approved in recent years, including immune checkpoint inhibitors. Experience with ipilimumab (CTLA-4 antagonist), nivolumab and pembrolizumab (PD-1 antagonists), and atezolizumab (PD-L1 antagonist) has shown that the impact on overall survival in cancer patients is paramount. Immune checkpoint inhibitors target the immune system and they can be applied across multiple cancers; the response rate is ranging from 20 to 40%. Many studies have shown that thyroid cancer (TC) cells produce cytokines and chemokines, inducing several tumor-promoting effects...
December 15, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29239194/-immunotherapy-of-renal-cell-carcinoma
#2
A Poprach, R Lakomý, T Büchler
Treatment of renal cell carcinoma is still palliative. Targeted therapy increases response rates and prolongs overall survival and progression-free survival compared with cytokines and chemotherapy. Checkpoint inhibitors constitute the up-date of therapeutic approaches, and anti-PD-1 antibody, one checkpoint inhibitor, is now well established as a second and/or third palliative treatment for patients with renal cell carcinoma. In this study, we present the latest data from current studies on cytokines, cancer vaccines, ipilimumab, and nivolumab...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/29239188/-evaluation-of-inflammatory-cells-tumor-infiltrating-lymphocytes-in-solid-tumors
#3
P Dundr, K Němejcová, M Bártů, R Matěj, Z Rohan, I Tichá
BACKGROUND: The tumor microenvironment plays an important role in tumorigenesis and the tumor-host relationship. An important part of the tumor microenvironment is inflammatory infiltration. Its evaluation in solid tumors has prognostic meaning and appears also to be predictive of outcome, which is particularly important for predicting responses to immune checkpoint inhibitors. However, the methodology used to assess inflammatory infiltration is problematic, because it has been standardized only for certain types of tumors...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/29238906/thyroid-dysfunctions-secondary-to-cancer-immunotherapy
#4
REVIEW
P Chalan, G Di Dalmazi, F Pani, A De Remigis, A Corsello, P Caturegli
BACKGROUND: Immunotherapy is a firmly established pillar in the treatment of cancer, alongside the traditional approaches of surgery, radiotherapy, and chemotherapy. Like every treatment, also cancer immunotherapy causes a diverse spectrum of side effects, collectively referred to as immune-related adverse events. OBJECTIVE: This review will examine the main forms of immunotherapy, the proposed mechanism(s) of action, and the incidence of thyroid dysfunctions. METHODS: A comprehensive MEDLINE search was performed for articles published up to March 30, 2017...
December 13, 2017: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/29237435/clinical-safety-of-combined-therapy-of-immune-checkpoint-inhibitors-and-viscum-album-l-therapy-in-patients-with-advanced-or-metastatic-cancer
#5
Anja Thronicke, Megan L Steele, Christian Grah, Burkhard Matthes, Friedemann Schad
BACKGROUND: Despite improvement of tumour response rates in patients with progressive and metastatic cancer, immune checkpoint inhibitors (ICM) induce toxicities in cancer patients. Viscum album L. (VA, mistletoe) extracts are applied as add-on cancer therapy especially in German speaking countries and within integrative and anthroposophical concepts with the goal to improve quality of life. The primary objective of this pilot observational cohort study was to determine the rate of adverse events (AE) related to ICM therapy with and without VA in patients with advanced or metastatic cancer in a certified Cancer Center...
December 13, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/29233542/natural-killer-cells-and-anti-tumor-immunity
#6
Sandra E Nicholson, Narelle Keating, Gabrielle T Belz
Immune checkpoint inhibitors harness the power of the immune system to fight cancer. The clinical success achieved with antibodies against the inhibitory T cell receptors PD-1 and CTLA4 has focused attention on the possibility of manipulating other immune cells, in particular those involved in innate immunity. Here we review the role of innate lymphoid cells (ILCs) and their contribution to tumor immunity. As the prototypical ILC, the natural killer (NK) cell has an intrinsic ability to detect and kill cancer cells...
December 9, 2017: Molecular Immunology
https://www.readbyqxmd.com/read/29230122/the-role-of-checkpoint-inhibition-in-non-small-cell-lung-cancer
#7
REVIEW
Jonathan Lu, Robert A Ramirez
Background: The development of immune checkpoint inhibitors has revolutionized the treatment of cancer. Their use in non-small cell lung cancer (NSCLC) remains in its infancy, but rapid progress has been made in treating metastatic NSCLC. Methods: This article outlines the role of immune checkpoint inhibitors in the treatment of malignancy and reviews clinical trials of novel immunotherapies in the setting of metastatic NSCLC. Results: Traditional chemotherapy with a platinum-based doublet has long been the backbone in the treatment of metastatic NSCLC...
2017: Ochsner Journal
https://www.readbyqxmd.com/read/29229461/predictive-markers-of-anti-vegf-and-emerging-role-of-angiogenesis-inhibitors-as-immunotherapeutics
#8
REVIEW
Priti S Hegde, Jeffrey J Wallin, Christoph Mancao
The critical role of angiogenesis in promoting tumor growth and metastasis has been well established scientifically, and consequently blocking this pathway as a therapeutic strategy has demonstrated great clinical success for the treatment of cancer. The holy grail however, has been the identification of patients who derive significant survival benefit from this class of agents. Here we attempt to delineate the diverse mechanisms related to anti-VEGF including its role as an anti-vascular, anti-angiogenic or an anti-permeability factor and review the most promising predictive biomarkers interrogated in large clinical trials, that identify patients who may derive significant survival advantage with VEGF inhibition...
December 8, 2017: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29228707/pd-l1-immunohistochemical-assays-for-assessment-of-therapeutic-strategies-involving-immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer-a-comparative-study
#9
Hyojin Kim, Hyun Jung Kwon, Soo Young Park, Eunhyang Park, Jin-Haeng Chung
Although immune checkpoints inhibitors have exhibited promising activity in clinical trials in non-small cell lung cancer (NSCLC) patients, the current programmed cell death-ligand 1 (PD-L1) assays are inconsistent in terms of the staining analysis and scoring system used. To verify the interchangeability of the available PD-L1 assays, we performed immunohistochemistry using three antibody clones used in clinical trials (22C3, SP263, and SP142) and the E1L3N clone as a laboratory developed test for 97 resected NSCLC specimens...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29226734/emerging-first-line-treatment-options-for-bladder-cancer-a-review-of-phase-ii-and-iii-therapies-in-the-pipeline
#10
Omer Jamy, Guru Sonpavde
The treatment of urothelial carcinoma (UC) had remained unchanged for several years until the recent FDA approval of immune checkpoint inhibitors (CPIs) in the salvage setting. Novel dual CPI-CPI and CPI-chemotherapy combinations are now being investigated aggressively as first line therapy for metastatic disease. Areas Covered: We discuss the recent insights into the tumor biology of UC, which may impact the prognosis as well as assist in developing precision medicine. This is followed by an overview of existing treatment including conventional chemotherapy as well as the trials that led to the recent approval of PD-1 and PD-L1 inhibitors...
December 10, 2017: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29224824/circulating-tumour-cell-pd-l1-test-for-head-and-neck-cancers
#11
Arutha Kulasinghe, Liz Kenny, Chamindie Punyadeera
Immune checkpoint inhibitors have gained traction over the last few years in the treatment of metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) patients. Monoclonal antibodies that block the programmed death 1 (PD-1) receptor and its major ligand, PD-L1, have shown durable responses and low toxicity profiles. There are currently no validated predictive biomarkers to select patients likely to respond to anti-PD-1/PD-L1 therapy to avoid unwanted side effects and to reduce healthcare expenditure...
December 2017: Oral Oncology
https://www.readbyqxmd.com/read/29224458/corticosteroids-for-the-management-of-immune-related-adverse-events-in-patients-receiving-checkpoint-inhibitors
#12
Kiersten J Williams, Dennis W Grauer, David W Henry, Michelle L Rockey
Introduction Due to enhanced T-cell activity, immune checkpoint inhibitors cause immune-related adverse effects. Corticosteroids are the mainstay of immune-related adverse effect management but the optimal strategy has not been determined, putting patients at risk for steroid-related adverse effects and potentially decreased efficacy of immunotherapy. This study aims to characterize the use of corticosteroids for the management of immune-related adverse effect. Methods and materials A retrospective, single-center evaluation of patients receiving checkpoint inhibitors was conducted...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29223828/rationale-for-combination-of-therapeutic-antibodies-targeting-tumor-cells-and-immune-checkpoint-receptors-harnessing-innate-and-adaptive-immunity-through-igg1-isotype-immune-effector-stimulation
#13
REVIEW
Robert L Ferris, Heinz-Josef Lenz, Anna Maria Trotta, Jesús García-Foncillas, Jeltje Schulten, François Audhuy, Marco Merlano, Gerard Milano
Immunoglobulin (Ig) G1 antibodies stimulate antibody-dependent cell-mediated cytotoxicity (ADCC). Cetuximab, an IgG1 isotype monoclonal antibody, is a standard-of-care treatment for locally advanced and recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and metastatic colorectal cancer (CRC). Here we review evidence regarding the clinical relevance of cetuximab-mediated ADCC and other immune functions and provide a biological rationale concerning why this property positions cetuximab as an ideal partner for immune checkpoint inhibitors (ICIs) and other emerging immunotherapies...
December 2, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29221649/-two-cases-of-granuloma-annulare-under-anti-pd1-therapy
#14
R Charollais, F Aubin, B Roche-Kubler, E Puzenat
BACKGROUND: Granuloma annulare as a granulomatous cutaneous reaction may be drug-induced. Immune checkpoint inhibitors including programmed death-1 (PD-1) inhibitors show remarkable antitumor activity and are approved for melanoma and other cancers. Different immune-related adverse effects have been described. We report herein a rare adverse effect of anti-PD1 therapy given for metastatic melanoma : granuloma annulare. PATIENTS AND METHODS: Two women receiving pembrolizumab metastatic melanoma presented with granuloma annulare...
December 5, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29220526/anti-pd-l1-treatment-induced-central-diabetes-insipidus
#15
Chen Zhao, Sri Harsha Tella, Jaydira Del Rivero, Anuhya Kommalapati, Ifechukwude Ebenuwa, James Gulley, Julius Strauss, Isaac Brownell
Context: Immune checkpoint inhibitors, including anti-PD-1, anti-PD-L1 and anti-CTLA4 monoclonal antibodies, have been widely used in cancer treatment. They are known to cause immune-related adverse events (irAEs), which resemble autoimmune diseases. Anterior pituitary hypophysitis with secondary hypopituitarism is a frequently reported irAE, especially in patients receiving anti-CTLA4 treatment. In contrast, posterior pituitary involvement, such as central diabetes insipidus (DI), is relatively rare and is unreported in patients undergoing PD-1/PD-L1 blockade...
December 6, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29216931/vista-deficiency-attenuates-antibody-induced-arthritis-and-alters-macrophage-gene-expression-in-response-to-simulated-immune-complexes
#16
Sabrina Ceeraz, Susan K Eszterhas, Petra A Sergent, David A Armstrong, Alix Ashare, Thomas Broughton, Li Wang, Dov Pechenick, Christopher M Burns, Randolph J Noelle, Matthew P Vincenti, Roy A Fava
BACKGROUND: In addition to activated T cells, the immune checkpoint inhibitor "V domain-containing Ig suppressor of T-cell activation" (VISTA) is expressed by myeloid cell types, including macrophages and neutrophils. The importance of VISTA expression by myeloid cells to antibody-induced arthritis and its potential for relevance in human disease was evaluated. METHODS: VISTA was immunolocalized in normal and arthritic human synovial tissue sections and synovial tissue lysates were subjected to western blot analysis...
December 8, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29212781/analysis-of-drug-development-paradigms-for-immune-checkpoint-inhibitors
#17
Denis L Jardim, Debora de Melo Gagliato, Francis J Giles, Razelle Kurzrock
Immune checkpoint inhibitors have unique toxicities and response kinetics compared to cytotoxics and gene-targeted anti-cancer agents. We investigated the impact of innovative/accelerated immunotherapy drug development/approval models on the accuracy of safety and efficacy assessments by searching the US Food and Drug Administration (FDA) website. Initial phase I trials for each agent were reviewed and safety and efficacy data compared to that found in later trials leading to regulatory approvals of the same agents...
December 6, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29212592/-immune-checkpoint-inhibitors-and-endocrinological-side-effects
#18
Line Bisgaard Jørgensen, Lars Bastholt, Knud Yderstræde
Immune checkpoint inhibitors including anti-cytotoxic T-lymphocyte-associated antigen-4 and anti-programmed cell death-1 have revolutionized cancer therapy but have also induced serious immune-related adverse events including hormonal dysfunction. The objective of this review is to characterize the incidence, clinical presentation, management and prognosis of the endocrine-related adverse events including hypophysitis, thyroid dysfunction and diabetes mellitus. Combination therapy is associated with an increased risk of adverse events...
December 4, 2017: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/29212254/distinct-mobilization-of-leukocytes-and-hematopoietic-stem-cells-by-cxcr4-peptide-antagonist-ly2510924-and-monoclonal-antibody-ly2624587
#19
Sheng-Bin Peng, Robert D Van Horn, Tinggui Yin, Robin M Brown, William C Roell, Victor H Obungu, Charles Ruegg, Victor J Wroblewski, Eyas Raddad, John R Stille
Stromal cell-derived factor-1 (SDF-1) and its receptor CXCR4 play a critical role in mobilization and redistribution of immune cells and hematopoietic stem cells (HSCs). We evaluated effects of two CXCR4-targeting agents, peptide antagonist LY2510924 and monoclonal antibody LY2624587, on mobilizing HSCs and white blood cells (WBCs) in humans, monkeys, and mice. Biochemical analysis showed LY2510924 peptide blocked SDF-1/CXCR4 binding in all three species; LY2624587 antibody blocked binding in human and monkey, with minimal activity in mouse...
November 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/29211297/immune-checkpoint-inhibitors-in-advanced-non-small-cell-lung-cancer
#20
REVIEW
Hazem I Assi, Alice O Kamphorst, Nour M Moukalled, Suresh S Ramalingam
The emergence of immune checkpoint inhibitors for the treatment of cancer has led to major changes to the therapeutic landscape of lung cancer. Improvements in overall survival relative to standard chemotherapy have been observed in the first-line and second-line therapy settings for patients with advanced non-small cell lung cancer (NSCLC) who are treated with immune checkpoint inhibitors. Consequently, every patient with advanced-stage NSCLC is now a candidate for immune checkpoint inhibitor therapy. However, it is clear that the benefit from therapy is not universal, and identification of biomarkers to select therapy has assumed importance...
December 6, 2017: Cancer
keyword
keyword
100072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"